CJC-1295 and Ipamorelin Explained: What the Research Actually Shows

What are CJC-1295 and ipamorelin?

CJC-1295 is a long-acting analog of growth-hormone-releasing hormone that acts at the pituitary GHRH receptor; ipamorelin is a ghrelin-receptor agonist that acts at GHS-R1a. Their receptors and signaling contexts differ. Human evidence here is limited to hormone-concentration findings, not trials showing better body composition, recovery, performance, sleep, or longevity in people.

1. What CJC-1295 is

For background on the broader category, see our overview of growth-hormone peptides. The distinction between a biological signal and a demonstrated outcome is especially important when two compounds are discussed together.

CJC-1295 is designed as an analog of growth hormone–releasing hormone (GHRH), the hypothalamic signal that helps regulate pituitary growth hormone release. Its target is the GHRH receptor, often written GHRH-R, on pituitary somatotrophs. Activating that receptor can increase the signal for endogenous GH secretion. This is not the same as administering GH, and it does not establish what a person will feel or achieve when GH concentrations change.

In this article, “CJC-1295” refers to the DAC-containing form studied in the primary human paper. DAC means Drug Affinity Complex: the molecular design extends exposure by enabling binding to serum albumin. The albumin association helps explain why this form has a longer pharmacokinetic profile than a short-lived GHRH fragment. The mechanism is a property of the compound, not evidence that longer exposure produces a particular health result.

Naming is a real source of confusion. CJC-1295 with DAC should not be treated as interchangeable with CJC-1295 without DAC, also called modified GRF 1-29 or Mod GRF. Those labels refer to different forms and different pharmacokinetic questions. The literature and commercial discussions sometimes use “CJC-1295” inconsistently, so a careful account should state which form is being discussed rather than infer it from the name alone.

2. What ipamorelin is

Ipamorelin is a growth hormone secretagogue: it acts as an agonist at GHS-R1a, the growth hormone secretagogue receptor 1a. GHS-R1a is commonly called the ghrelin receptor because it is the receptor through which ghrelin and related signals can stimulate GH release. That is a different entry point from the GHRH receptor. The two pathways can influence the same pituitary output while remaining pharmacologically distinct.

The original ipamorelin research described relative selectivity for GH release. In a rat study, ipamorelin produced GH release with less ACTH and prolactin stimulation than the comparator secretagogues GHRP-6 and GHRP-2.2 “Relative selectivity” is the accurate phrase: the finding does not mean absolute specificity, does not erase activity elsewhere in the ghrelin-receptor system, and does not prove safety or the same selectivity in humans.

Ghrelin biology extends beyond GH. Ghrelin participates in appetite, gastrointestinal motility, and energy homeostasis, as the foundational discovery paper illustrates.3 Therefore, a GHS-R1a agonist may engage a wider biological network than a simple "GH switch" description suggests. Recognizing those pathways is an acknowledgment of receptor biology, not a claim that a particular person will experience a particular benefit or adverse effect.

3. Why they are not interchangeable

CJC-1295 and ipamorelin are sometimes grouped together because both can increase GH secretion, but a shared downstream hormone does not make them the same intervention. CJC-1295 engages pituitary GHRH-R signaling. Ipamorelin engages GHS-R1a, the receptor associated with ghrelin and other secretagogues. Receptor location, ligand context, feedback relationships, and intracellular signaling can all differ before GH appears in a blood sample.

Their non-GH biology also differs. The GHRH pathway is principally discussed in the context of pituitary GH regulation, while GHS-R1a belongs to a system involved in appetite, GI motility, and energy balance. That does not by itself predict a clinical outcome, but it is enough to reject the idea that one compound is simply a substitute for the other. It also means that combining names in a “stack” is not a scientifically neutral shorthand. Our article on what a peptide stack means explains why combination claims require separate evidence rather than additive assumptions.

The same caution applies to comparisons with growth hormone itself. A secretagogue or GHRH analog stimulates an endogenous regulatory system; exogenous GH administration is a different exposure. Results from one cannot automatically be transferred to another. Even within the peptide category, receptor mechanism and formulation matter more than a shared marketing label.

4. What human research shows

CJC-1295: a hormone-concentration study

The primary human evidence in this packet is Teichman and colleagues’ 2006 phase 2 study in healthy adult volunteers.1 It examined CJC-1295 and measured concentrations of GH and insulin-like growth factor 1 (IGF-1), reporting sustained stimulation. Those are meaningful pharmacodynamic measurements: they show that the studied compound affected the endocrine signals the investigators set out to measure.

They are not outcome measurements. The study did not test body composition, exercise performance, injury recovery, sleep quality, functional capacity, or longevity. It therefore cannot establish that sustained GH or IGF-1 elevation improves any of those endpoints. It also should not be summarized as a trial of general wellness. “The hormone changed” is a narrower and more defensible conclusion than “the person improved.”

There is no equivalent human CJC-1295 body-composition trial in this evidence packet. The absence of that trial does not prove that no research exists anywhere, but it does set a boundary for what can responsibly be claimed from these sources. A reader evaluating a new claim should ask what was measured, in whom, for how long, and whether the endpoint was a laboratory concentration or a patient-important outcome.

Ipamorelin: no clinical outcome evidence here

There is no human ipamorelin clinical-outcome trial in this evidence packet. The key ipamorelin paper by Raun and colleagues is an animal study, not a human trial.2 It supports a mechanistic description of relative GH selectivity in rats; it does not demonstrate improved body composition, recovery, performance, sleep, or longevity in people. Nor does it establish long-term safety in humans.

This distinction is easy to lose when a compound is described with a confident adjective such as "selective." Selectivity is a comparative experimental result under defined conditions. It is not a guarantee of receptor exclusivity, a clinical-effect claim, or permission to extrapolate from an animal model to everyday human use.

5. What animal and laboratory evidence can—and cannot—tell us

Animal and cell or laboratory findings are valuable for asking how a molecule interacts with a receptor and which hormones respond. Raun 1998 is useful in exactly that way: in rats, ipamorelin’s GH response was relatively separated from ACTH and prolactin stimulation compared with GHRP-6 and GHRP-2.2 That result helps distinguish ipamorelin’s pharmacology from a vague claim that all secretagogues behave alike.

But a rat response is not a human clinical endpoint. Species differ in receptor distribution, physiology, metabolism, and feedback. Laboratory selectivity under a particular assay is also not absolute specificity across every tissue. These limits do not make the study unhelpful; they define the question it can answer. It informs mechanism and hypothesis generation, not whether a person will gain muscle, heal faster, or live longer.

The ghrelin discovery literature adds context rather than an efficacy result. Ghrelin was identified as an acylated peptide from the stomach with GH-releasing activity, while also belonging to broader appetite and energy-regulation biology.3 A receptor agonist built around that system should be evaluated with that full biology in mind, not reduced to one downstream concentration.

6. The evidence gaps that matter

An increase in GH or IGF-1 is an intermediate biological observation. It is not proof of improved body composition, recovery, athletic performance, sleep, or longevity. The systematic review by Liu and colleagues is relevant as context, not as a direct trial of either peptide: it evaluated exogenous GH administration in healthy older adults, not CJC-1295 or ipamorelin.4 Its findings illustrate why raising an endocrine marker and improving health are separate questions, including the importance of adverse effects observed with GH administration itself.

Long-term safety remains uncertain in this packet. Short-term hormone measurements cannot settle questions about prolonged endocrine stimulation, glucose regulation, tissue effects, cardiovascular outcomes, or other risks. A mechanistic argument may identify what should be monitored, but it cannot replace long-duration, adequately controlled human outcomes research.

Regulatory status and safety assessment are also not interchangeable with a study result. The FDA compounding safety page lists CJC-1295 and ipamorelin in separate compound entries and should be read as regulatory safety information, not as evidence that either compound improves a health endpoint.56 For readers also considering the Repair Protocol book, the same evidence rule applies: an appealing biological rationale is not a substitute for a demonstrated outcome.

Frequently asked questions

Are CJC-1295 and ipamorelin the same peptide?

No. CJC-1295 is a GHRH analog acting at pituitary GHRH-R, while ipamorelin is a ghrelin-receptor agonist acting at GHS-R1a. They may both influence GH release, but their receptor targets and broader biology differ.

Does CJC-1295 without DAC mean the same thing as CJC-1295?

Not necessarily. This article uses CJC-1295 for the DAC-containing form, whose albumin-binding Drug Affinity Complex extends exposure. CJC-1295 without DAC, also called modified GRF 1-29 or Mod GRF, is a different form; terminology is used inconsistently.

What did the main CJC-1295 human study actually show?

Teichman 2006 studied healthy adult volunteers and measured GH and IGF-1 concentrations, finding sustained stimulation. It did not measure body composition, performance, injury recovery, sleep quality, or longevity, so those outcomes cannot be inferred from the paper.

Does ipamorelin selectively affect only growth hormone?

No such absolute claim is supported here. Raun 1998 found relatively selective GH release with less ACTH and prolactin stimulation than comparator secretagogues in rats. That is an animal-model comparison, not proof of absolute specificity or human safety.

Do higher GH or IGF-1 concentrations prove better health?

No. Concentrations are intermediate biomarkers, not proof of improved body composition, recovery, performance, sleep, or longevity. Those claims require appropriate human outcome trials, and this evidence packet does not provide them for these peptides.

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799–805. PMID 16352683; doi:10.1210/jc.2005-1536 ↗
2. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552–561. PMID 9849822; doi:10.1530/eje.0.1390552 ↗
3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. “Ghrelin is a growth-hormone-releasing acylated peptide from stomach.” Nature. 1999;402(6762):656–660. PMID 10604470; doi:10.1038/45230 ↗
4. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR. “Systematic review: the safety and efficacy of growth hormone in the healthy elderly.” Annals of Internal Medicine. 2007;146(2):104–115. PMID 17227934; doi:10.7326/0003-4819-146-2-200701160-00005 ↗
5. U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.” FDA compounding safety information; CJC-1295 entry ↗
6. U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.” FDA compounding safety information; ipamorelin entry ↗

This article is for educational purposes and is not medical advice.